01530 3SBIO
- 6.100
- -0.130-2.09%
3SBIO News
May 29 Repurchase Collection | Tencent Holdings, AIA and others bought back one after another, of which Tencent Holdings spent HK$1.03 billion
According to documents disclosed by the Hong Kong Stock Exchange on May 30, $Tencent Holdings (00700.HK) $, $AIA (01299.HK) $, etc. repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 2.68 million common shares on May 29, involving an amount of HK$1,003 billion. The repurchase price per share ranged from HK$379.8 to HK$369.8. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 22.1 million shares, accounting for 0.235% of the number of shares issued when the ordinary resolution was passed. ② $AIA (
Sansheng Pharmaceutical (01530.HK) spent HK$4.37 million to buy back 702,500 shares on May 29
Gelonghui, May 29丨Sansheng Pharmaceutical (01530.HK) announced that it spent HK$4.37 million to buy back 702,500 shares on May 29.
Selected announcements | CITIC Group plans to acquire 60% of Huarong Jinleu's shares for 12 billion yuan; Gome retail will issue new shares at a premium of 3547.06% to settle 145 million yuan bonds
China Evergrande's liquidators have yet to find a restructuring plan that would enable the company to meet the resumption guidelines and resume share trading, and continues to suspend trading; Sansheng Mandy, a subsidiary of Sansheng Pharmaceutical, and Hanyu Pharmaceutical reached a cooperation agreement on simeglutide injections.
3SBio Subsidiary Strikes Key Weight Management Drug Deal
Sansheng Pharmaceutical (01530.HK): Sansheng Mandy and Hanyu Pharmaceutical reached a cooperation agreement on simeglutide injections
Gelonghui, May 28, 丨 Sansheng Pharmaceutical (01530.HK) announced that Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. (“Sansheng Mandi”), a wholly-owned subsidiary of Shenyang Sansheng Pharmaceutical Co., Ltd., a subsidiary of the Company, signed a “Simeglutide Injection Cooperation Agreement” (“Agreement”) with Shenzhen Hanyu Pharmaceutical Co., Ltd. (“Hanyu Pharmaceutical”). According to the agreement, Hanyu Pharmaceutical and Sansheng Mandi will jointly develop, exclusively supply/procure and sell simeglutide injections (weight loss indications) (“simeglutide injections (weight loss indications)”). Sansheng Mandi will agree to Hanyu Pharmaceutical in accordance with the agreement
3SBio Inc. Schedules Annual General Meeting
Improve quality and expand! The National Health Insurance Administration issued a new collection document “There is a lot of information” to set the tone for new trends in collection and procurement
① Yesterday evening, the National Health Insurance Administration issued the “Notice on Strengthening Regional Collaboration to Improve Quality and Expand Centralized Pharmaceutical Procurement in 2024", which provides further instructions on “improving quality and expansion” of collection; ② Many interprovincial alliance procurement will soon be upgraded to national joint procurement, which has attracted strong attention from the industry. In particular, the provinces covered by the Sanming Alliance and Henan Alternative Medicine Alliance will be further expanded, and proprietary Chinese medicine and Chinese medicine tablet companies need to prepare early.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
May 16 Repurchase Collection | Hang Seng Bank, MGM China and others bought back one after another, of which Hang Seng Bank spent HK$32.912,600
According to HKEx disclosure documents on May 17, $Hang Seng Bank (00011.HK) $ and $MGM China (02282.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 300,000 common shares on May 16, involving an amount of HK$32.912,600. The repurchase price per share ranged from HK$111.7 to HK$107.7. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 1.8 million shares, accounting for 0.094% of the number of shares issued when the ordinary resolution was passed. ② $MGM Middle
Sansheng Pharmaceutical (01530) spent HK$2,629,800 to buy back 409,000 shares on May 16
Sansheng Pharmaceutical (01530) announced that on May 16, 2024, the company spent HK$2,629,800...
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
May 13 Repurchase Collection | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$217 million
According to HKEx disclosure documents on May 14, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.1976 million common shares on May 10, involving an amount of HK$217 million. The repurchase price per share ranged from HK$68.15 to HK$67.8. ② $Hang Seng Bank (00011.HK) $ repurchased 300,000 common shares on May 13, involving an amount of HK$32.698,700. The repurchase price per share ranged from HK$109.4 to HK$10
Sansheng Pharmaceutical (01530.HK) spent HK$3.99 million to buy back 600,000 shares on May 13
Gelonghui, May 13 | Sansheng Pharmaceutical (01530.HK) announced that it spent HK$3.99 million to buy back 600,000 shares on May 13.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
三生製藥：2023 年度報告
Sansheng Pharmaceutical (01530.HK) was granted an additional 982,400 shares of common stock by Lou Jing, worth approximately HK$7.502 million
On April 24, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 24, 2023, Lou Jing increased his common stock holdings of $Sansheng Pharmaceutical (01530.HK) by $982,400 at an average price of HK$7.6365 per share, worth about HK$7.502 million. After the increase in holdings, Lou Jing's latest shareholding was 528 million shares, and the good position ratio increased from 21.63% to 21.67%. Additional Information: Dr. Lou Jing is an enforcer and a benefit of an unname
Repurchase Collection on April 22 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$78.0367 million
According to HKEx's April 23 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 1,266,800 common shares on April 19, involving an amount of HK$78.367 million. The repurchase price per share ranged from HK$62 to HK$61.25. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 22, involving an amount of HK$58.405 million. The repurchase price per share ranged from HK$98.7 to HK$9
Sansheng Pharmaceutical (01530.HK): Zhang Dan intends to retire as an independent non-executive director
Gelonghui, April 22 | Sansheng Pharmaceutical (01530.HK) announced that Zhang Dan, an independent non-executive director, will step down in rotation at the company's annual general meeting of shareholders to be held on June 25, 2024. Independent non-executive director Wong Cho-yiu has been appointed by the board of directors as a member of the Remuneration Committee, effective immediately after the 2023 Annual General Meeting of Shareholders to be held on June 25, 2024.
Sansheng Pharmaceutical (01530): Wong Cho-yiu appointed as a member of the Remuneration Committee
Sansheng Pharmaceutical (01530) issued an announcement. According to the company's articles of association, Zhang Dan, an independent non-executive director, will...
Analysis
Price Target
No Data
